vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Wheels Up Experience Inc. (UP). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $183.8M, roughly 1.3× Wheels Up Experience Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -15.7%, a 26.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -10.2%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-58.3M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -3.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Wheels Up is a provider of "on demand" private aviation in the United States and one of the largest private aviation companies in the world. It was founded in 2013 by Kenny Dichter, using a membership/on-demand business model. Wheels Up members can book private aircraft from the company fleet and third-party operators using a mobile application.
ANIP vs UP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $183.8M |
| Net Profit | $27.5M | $-28.9M |
| Gross Margin | — | 14.3% |
| Operating Margin | 14.1% | -0.9% |
| Net Margin | 11.1% | -15.7% |
| Revenue YoY | 29.6% | -10.2% |
| Net Profit YoY | 367.5% | 67.0% |
| EPS (diluted) | $1.14 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $183.8M | ||
| Q3 25 | $227.8M | $185.5M | ||
| Q2 25 | $211.4M | $189.6M | ||
| Q1 25 | $197.1M | $177.5M | ||
| Q4 24 | $190.6M | $204.8M | ||
| Q3 24 | $148.3M | $193.9M | ||
| Q2 24 | $138.0M | $196.3M | ||
| Q1 24 | $137.4M | $197.1M |
| Q4 25 | $27.5M | $-28.9M | ||
| Q3 25 | $26.6M | $-83.7M | ||
| Q2 25 | $8.5M | $-82.3M | ||
| Q1 25 | $15.7M | $-99.3M | ||
| Q4 24 | $-10.3M | $-87.5M | ||
| Q3 24 | $-24.2M | $-57.7M | ||
| Q2 24 | $-2.3M | $-97.0M | ||
| Q1 24 | $18.2M | $-97.4M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 8.3% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 13.9% | ||
| Q3 24 | — | 13.9% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | -0.6% |
| Q4 25 | 14.1% | -0.9% | ||
| Q3 25 | 15.9% | -33.1% | ||
| Q2 25 | 6.6% | -31.4% | ||
| Q1 25 | 13.3% | -45.5% | ||
| Q4 24 | -2.3% | -26.0% | ||
| Q3 24 | -13.8% | -21.6% | ||
| Q2 24 | 3.7% | -40.3% | ||
| Q1 24 | 14.8% | -42.9% |
| Q4 25 | 11.1% | -15.7% | ||
| Q3 25 | 11.7% | -45.1% | ||
| Q2 25 | 4.0% | -43.4% | ||
| Q1 25 | 8.0% | -55.9% | ||
| Q4 24 | -5.4% | -42.7% | ||
| Q3 24 | -16.3% | -29.8% | ||
| Q2 24 | -1.7% | -49.4% | ||
| Q1 24 | 13.2% | -49.4% |
| Q4 25 | $1.14 | $-0.04 | ||
| Q3 25 | $1.13 | $-0.12 | ||
| Q2 25 | $0.36 | $-0.12 | ||
| Q1 25 | $0.69 | $-0.14 | ||
| Q4 24 | $-0.45 | $-0.13 | ||
| Q3 24 | $-1.27 | $-0.08 | ||
| Q2 24 | $-0.14 | $-0.14 | ||
| Q1 24 | $0.82 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $133.9M |
| Total DebtLower is stronger | — | $671.3M |
| Stockholders' EquityBook value | $540.7M | $-392.1M |
| Total Assets | $1.4B | $968.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $133.9M | ||
| Q3 25 | $262.6M | $125.3M | ||
| Q2 25 | $217.8M | $107.0M | ||
| Q1 25 | $149.8M | $171.8M | ||
| Q4 24 | $144.9M | $216.4M | ||
| Q3 24 | $145.0M | $115.9M | ||
| Q2 24 | $240.1M | $141.5M | ||
| Q1 24 | $228.6M | $180.9M |
| Q4 25 | — | $671.3M | ||
| Q3 25 | — | $766.5M | ||
| Q2 25 | — | $770.5M | ||
| Q1 25 | — | $765.8M | ||
| Q4 24 | — | $761.3M | ||
| Q3 24 | — | $596.9M | ||
| Q2 24 | — | $597.4M | ||
| Q1 24 | — | $603.2M |
| Q4 25 | $540.7M | $-392.1M | ||
| Q3 25 | $505.8M | $-374.5M | ||
| Q2 25 | $436.8M | $-347.8M | ||
| Q1 25 | $418.6M | $-288.1M | ||
| Q4 24 | $403.7M | $-202.1M | ||
| Q3 24 | $405.9M | $-117.7M | ||
| Q2 24 | $455.8M | $-72.2M | ||
| Q1 24 | $452.0M | $936.0K |
| Q4 25 | $1.4B | $968.8M | ||
| Q3 25 | $1.4B | $973.0M | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.0B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 644.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-18.4M |
| Free Cash FlowOCF − Capex | $29.1M | $-58.3M |
| FCF MarginFCF / Revenue | 11.8% | -31.7% |
| Capex IntensityCapex / Revenue | 0.5% | 21.7% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-259.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-18.4M | ||
| Q3 25 | $44.1M | $-37.1M | ||
| Q2 25 | $75.8M | $-62.9M | ||
| Q1 25 | $35.0M | $-47.9M | ||
| Q4 24 | $15.9M | $37.9M | ||
| Q3 24 | $12.5M | $-16.9M | ||
| Q2 24 | $17.4M | $-25.2M | ||
| Q1 24 | $18.3M | $-73.8M |
| Q4 25 | $29.1M | $-58.3M | ||
| Q3 25 | $38.0M | $-60.4M | ||
| Q2 25 | $71.8M | $-78.6M | ||
| Q1 25 | $32.5M | $-62.6M | ||
| Q4 24 | $13.5M | $-70.2M | ||
| Q3 24 | $7.7M | $-21.9M | ||
| Q2 24 | $13.0M | $-30.8M | ||
| Q1 24 | $13.7M | $-77.8M |
| Q4 25 | 11.8% | -31.7% | ||
| Q3 25 | 16.7% | -32.6% | ||
| Q2 25 | 34.0% | -41.5% | ||
| Q1 25 | 16.5% | -35.3% | ||
| Q4 24 | 7.1% | -34.3% | ||
| Q3 24 | 5.2% | -11.3% | ||
| Q2 24 | 9.4% | -15.7% | ||
| Q1 24 | 10.0% | -39.5% |
| Q4 25 | 0.5% | 21.7% | ||
| Q3 25 | 2.7% | 12.5% | ||
| Q2 25 | 1.9% | 8.3% | ||
| Q1 25 | 1.3% | 8.3% | ||
| Q4 24 | 1.3% | 52.8% | ||
| Q3 24 | 3.2% | 2.6% | ||
| Q2 24 | 3.2% | 2.9% | ||
| Q1 24 | 3.3% | 2.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
UP
Segment breakdown not available.
